{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:13:44Z","timestamp":1785510824798,"version":"3.56.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.yexmp.2026.105039","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:31:42Z","timestamp":1773700302000},"page":"105039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer"],"prefix":"10.1016","volume":"146","author":[{"given":"Toru","family":"Sakatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Jinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bresee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen T.M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Luthringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Contreras-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Rosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2026.105039_bb0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","article-title":"A CXCL1 paracrine network links cancer chemoresistance and metastasis","volume":"150","author":"Acharyya","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.yexmp.2026.105039_bb0010","article-title":"Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy","volume":"16","author":"Contreras-Sanz","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yexmp.2026.105039_bb0015","article-title":"Analytical validation of ONCURIA a multiplex bead-based immunoassay for the non-invasive bladder cancer detection","volume":"22","author":"Furuya","year":"2020","journal-title":"Pract. Lab. Med."},{"key":"10.1016\/j.yexmp.2026.105039_bb0020","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.7150\/thno.15625","article-title":"Role of the CXCL8-CXCR1\/2 axis in cancer and inflammatory diseases","volume":"7","author":"Ha","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.yexmp.2026.105039_bb0025","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1158\/1078-0432.CCR-07-1922","article-title":"Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer","volume":"14","author":"Kawanishi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105039_bb0030","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/labinvest.2013.71","article-title":"Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1\/2 and EGF pathways","volume":"93","author":"Miyake","year":"2013","journal-title":"Lab. Investig."},{"key":"10.1016\/j.yexmp.2026.105039_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-322","article-title":"Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers","volume":"13","author":"Miyake","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.yexmp.2026.105039_bb0040","doi-asserted-by":"crossref","first-page":"853","DOI":"10.7150\/thno.29553","article-title":"Monoclonal antibody against CXCL1 (HL2401) as a novel agent in suppressing IL6 expression and tumoral growth","volume":"9","author":"Miyake","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.yexmp.2026.105039_bb0045","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.yexmp.2026.105039_bb0050","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3233\/CBM-150472","article-title":"Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer","volume":"15","author":"Nakashima","year":"2015","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.yexmp.2026.105039_bb0055","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/1535-7163.MCT-11-0915","article-title":"The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models","volume":"11","author":"Ning","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.yexmp.2026.105039_bb0060","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.yexmp.2026.105039_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102528","article-title":"Development and analytical validation of a multiplex diagnostic qPCR-array as a potential application in predicting the response to neoadjuvant chemotherapy in muscle invasive bladder cancer","volume":"61","author":"Sakatani","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.yexmp.2026.105039_bb0070","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.yexmp.2026.105039_bb0075","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.yexmp.2026.105039_bb0080","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1158\/0008-5472.CAN-16-3199","article-title":"CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res."}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480026000183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480026000183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:20:58Z","timestamp":1781684458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480026000183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":16,"alternative-id":["S0014480026000183"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2026.105039","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2026.105039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105039"}}